10-Q: cbdMD Inc. Reports Q2 2024 Results Amidst Restructuring Efforts

cbdMD, Inc. reported a net loss for the second quarter of 2024, while implementing cost-cutting measures and strategic shifts to improve profitability.

Summary

• cbdMD, Inc. reported a net loss of $4.01 million for the second quarter of 2024, compared to a net loss of $2.34 million in the same period last year.
• Net sales decreased to $4.38 million, down from $6.24 million in the prior year's quarter.
• The company's cost of sales increased to 41% of net sales, up from 35.6% in the prior year's quarter.
• Operating expenses decreased to $4.13 million, down from $5.42 million in the same quarter of the previous year.
• The company is implementing cost-cutting measures, targeting a $200,000 per month reduction in G&A expenses by August.
• A new convertible note was issued for $1.25 million, with a fair market value of $2.7 million at the end of the quarter.
• The company is focusing on product innovation, expanding revenue channels, and international expansion.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is taking steps to reduce costs and diversify its product line, the significant decrease in sales and increase in net loss are concerning. The company's reliance on convertible notes for funding also adds to the risk. The sentiment is cautiously negative.

Positives

• Operating expenses decreased by $1.3 million or 25% for the three months ended March 31, 2024 compared to the same period in 2023.
• The company is actively pursuing cost-cutting measures, targeting a $200,000 per month reduction in G&A expenses by August.
• The company launched a new functional mushroom line under the ATRx brand, expanding its product portfolio.
• The company expanded its retail reach by launching products in Sprouts Supermarkets and Door Dash.
• The company is seeing wholesale opportunities begin to pick up and is optimistic about international opportunities.

Negatives

• Net sales decreased by $1.9 million or 29% for the three months ended March 31, 2024 compared to the same period in 2023.
• The company reported a net loss of $4.01 million for the second quarter of 2024.
• The cost of sales increased to 41% of net sales, up from 35.6% in the prior year's quarter.
• The company's working capital position may not be sufficient to support daily operations for the next twelve months.
• The company was unable to get the required votes to amend the Series A Preferred Stock designation.

Risks

• The company's working capital position may not be sufficient to support daily operations for the next twelve months.
• The company's ability to continue as a going concern is dependent on improving profitability and acquiring additional funding.
• The company faces challenges in the wholesale channel due to macro industry contraction trends.
• The company's current capital structure, specifically the overhang of the Series A Preferred stock, has stalled M&A prospects.
• The company is subject to regulatory risks associated with the CBD industry.

Future Outlook

The company is focused on improving profitability through cost reductions, product innovation, and expanding revenue channels. Management believes that the cost reduction initiatives should allow the company to operate close to a positive non-GAAP adjusted EBITDA run rate.

Management Comments

• Management continues to be very focused on delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.
• While revenue in the second quarter was challenging, we remain focused on top line improvements during 2024.
• We believe the combined market capitalization of both our common and Series A Preferred is being impacted due to our current capital structure.
• Our goal is to simplify our capital structure and we believe it will help unlock additional equity value and open up more strategic activity for the Company.
• Based on current revenue run rates, these in-place initiatives should allow the Company to operate close to a positive non-GAAP adjusted EBITDA run rate.

Industry Context

The CBD industry is facing challenges, including macro industry contraction trends and regulatory uncertainty. cbdMD is attempting to navigate these challenges by focusing on product innovation, cost reduction, and expanding its reach through various channels.

Comparison to Industry Standards

• The company's decrease in net sales and increase in cost of sales are concerning when compared to industry leaders who are showing growth and improved margins.
• The company's operating expense reduction is a positive sign, but it needs to be sustained to achieve profitability.
• The company's adjusted EBITDA loss is still significant, indicating that further cost-cutting and revenue growth are needed to reach industry benchmarks.
• The company's reliance on convertible notes for funding is a common practice in the industry, but it also adds to the company's financial risk.
• The company's expansion into functional mushrooms is a strategic move to diversify its product portfolio and potentially capture a new market segment, similar to other companies in the wellness space.

Legal Proceedings

• The company's sub landlord HSKL for its Red Oak Facility, filed a Complaint in Summary Ejectment filed in Mecklenburg County, North Carolina on February 27, 2024.
• Subject to compliance with the License Agreement and Lease Forbearance Agreement, HSKL has agreement to dismiss the complaint.

Stakeholder Impact

• Shareholders are impacted by the decrease in net sales and increase in net loss.
• Employees are impacted by the cost-cutting measures, including potential payroll reductions.
• Customers may benefit from the company's focus on product innovation and expansion of product offerings.
• Suppliers may be impacted by the company's cost-cutting measures and potential changes in purchasing patterns.
• Creditors are impacted by the company's reliance on convertible notes for funding.

Next Steps

• The company will continue to implement cost-cutting measures, targeting a $200,000 per month reduction in G&A expenses by August.
• The company will focus on product innovation, expanding revenue channels, and international expansion.
• The company will continue to evaluate M&A opportunities.
• The company will continue to monitor and address the regulatory environment for CBD.

Key Dates

Keywords

CBD, cannabidiol, hemp, ATRx, Paw CBD, net sales, operating expenses, net loss, convertible note, cost cutting, functional mushrooms, wholesale, e-commerce